Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 358

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NT-proBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease

Mueller, Thomas, Gegenhuber, Alfons, Poelz, Werner, Haltmayer, Meinhard · 2003 · Clinical Chemistry

Abstract

The amino-terminal fragment of the B-type natriuretic peptide prohormone (NT-proBNP) is a marker for functional cardiac impairment and is increased in heart disease with or without symptoms of heart failure (HF) (1). There are indications that currently used assays for NT-proBNP may differ in their cross-reactivity with circulating NT-proBNP split products and may also be affected by breakdown products of NT-proBNP produced after blood collection (2). A newer generation assay, a commercially available competitive enzyme immunoassay (EIA) for NT-proBNP (Biomedica Gruppe) (3) that does not require sample pretreatment, has been used in various methodologic and clinical studies (4)(5)(6), but noncompetitive immunoassays may offer advantages of better speed, sensitivity, precision, and possibly specificity over competitive immunoassays (7). Recently, a noncompetitive immunoassay for NT-proBNP has been developed (8). A fully automated version of this assay (Roche Diagnostics) has now been cleared by the US Food and Drug Administration. Our aim was to compare the Biomedica and Roche NT-proBNP assays, addressing whether the predictive values of both assays are similar with respect to structural heart disease with or without symptoms of HF. The present study, carried out at the Division of Internal Medicine, St. John of God Hospital (Linz, Austria), was approved by the local ethics committee in accordance to the Helsinki Declaration. We prospectively recruited 157 consecutive patients admitted for extensive cardiac evaluation (including performance of bicycle ergometry) and 23 consecutive patients with symptomatic HF admitted for inpatient treatment; all participants gave written informed consent. Study participants were classified according to the American College of Cardiology/American Heart Association guidelines for the evaluation and management of chronic HF in the adults (9) to one of the four following categories: (a) healthy individuals (n = 42); (b) patients at high risk for developing HF but without structural disorders of the heart (HF stage A; n = 39); (c) patients with structural disorders of the heart but without symptoms of HF (HF stage B; n = 56); and (d) patients with past or current symptoms of HF associated with underlying structural heart disease (HF stage C; n = 43). None of the study participants belonged to HF stage D according to the above guidelines (patients with end stage disease requiring specialized treatment strategies). This classification was done by one experienced cardiologist (one of the investigators) blinded to the NT-proBNP results and was based on detailed anamnesis with evaluation of the patients’ medical reports, appropriate risk factor assessment, physical examination, 12-lead electrocardiography, chest radiography, two-dimensional echocardiography coupled with Doppler flow studies, bicycle ergometry (in the 157 consecutive patients admitted for extensive cardiac evaluation), and an ongoing assessment of the patients’ clinical status. Normal echocardiographic findings (i.e., individuals without structural disorders of the heart) were defined by a left ventricular end-diastolic diameter <56 mm without left ventricular hypertrophy or without wall motion abnormities, a right ventricular systolic pressure <35 mmHg, and a left ventricular ejection fraction >60%. No attempt was made to define diastolic HF. Drug therapy (i.e., angiotensin-converting enzyme inhibitors, beta-blockers, digitalis, and diuretics) was recorded at the day of blood collection and was modified in the sequel. The demographic and clinical characteristics of the study participants are listed in Table 1 . Patient characteristics according to HF classification. Age, body mass index, and biochemical markers are presented as median (25th–75th percentiles). Study participants were classified according to American College of Cardiology/American Heart Association guidelines (9). HF stage A, patients at high risk for developing HF but without structural heart disease; HF stage B, patients with structural heart disease but who have never developed symptoms of HF; HF stage C, patients with past or current symptoms of HF associated with underlying structural heart disease. BMI, body mass index; CAD, coronary artery disease; NYHA, New York Heart Association HF class; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LV left ventricle; CMP, cardiomyopathy; ACE, angiotensin-converting enzyme. Patient characteristics according to HF classification. Age, body mass index, and biochemical markers are presented as median (25th–75th percentiles). Study participants were classified according to American College of Cardiology/American Heart Association guidelines (9). HF stage A, patients at high risk for developing HF but without structural heart disease; HF stage B, patients with structural heart disease but who have never developed symptoms of HF; HF stage C, patients with past or current

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/49.6.976

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Mueller, T., Gegenhuber, A., Poelz, W., & Haltmayer, M.
Venue
Clinical Chemistry
Published
2003-06-01
Volume
49
Issue
6
Pages
976-979
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2153396461
Cited by
358
References
10
FWCI
59.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.